Long-term effects of tetrabenazine in hyperkinetic movement disorders
Long-term effects of tetrabenazine in hyperkinetic movement disorders
复制标题
DOI：
10.1212/wnl.48.2.358
复制
发表时间：
1997-02-01
期刊：
影响因子：
9.9
通讯作者：
Beach, J
中科院分区：
文献类型：
--
作者：
Jankovic, J;Beach, J
在过去 15 年里，Me 使用丁苯那嗪 (TBZ)（一种单胺消耗药物和多巴胺受体阻断药物）治疗了 526 名患有严重多动性运动障碍的患者。我们在此报告了 400 名经过充分随访的患者的结果。反应按 1 至 5 级评分（1 = 显着改善，4 = 无反应，5 = 恶化），并在最初和最后一次就诊时进行评估。 TBZ 治疗的平均持续时间为 28.9 个月（+/-31.1；范围，0.25 至 180 个月）。 93 名迟发性刻板症患者中，89.2% 的总体反应评级为 1（显着改善），12 名肌阵挛患者中的 89.3%，29 名亨廷顿病患者中的 82.8%，82 名迟发性肌张力障碍患者中的 80.5%，29 名其他运动障碍患者中的 79.3%，108 名患有肌阵挛的患者中 62.9%特发性肌张力障碍，47 名抽动秽语综合症患者中的 57.4% 患有此症。最常见的副作用包括嗜睡（36.5%）、帕金森症（28.5%）、抑郁（15.0%）、失眠（11.0%）、紧张或焦虑（10.3%）和静坐不能（9.5%）。通过减少剂量来控制副作用。 TBZ是治疗多种多动性运动障碍的有效且安全的药物，与典型的精神安定药相比，TBZ尚未被证明会引起迟发性运动障碍。
Over the past 15 years Me have treated 526 patients with severe hyperkinetic movement disorders with tetrabenazine (TBZ), a monoamine-depleting and a dopamine-receptor-blocking drug. We report here the results in 400 patients with adequate follow-up. The response was rated on a scale of 1 to 5 (1 = marked improvement, 4 = no response, 5 = worsening) and was assessed initially and at the last clinic visit. The average duration of TBZ treatment was 28.9 months (+/-31.1; range, 0.25 to 180 months). The global response rating of 1 (marked improvement) was recorded in 89.2% of 93 patients with tardive stereotypy, 89.3% of 12 with myoclonus, 82.8% of 29 with Hunting-ton's disease, 80.5% of 82 with tardive dystonia, 79.3% of 29 with other movement disorders, 62.9% of 108 with idiopathic dystonia, and in 57.4% of 47 with Tourette's syndrome. The most common side effects included drowsiness (36.5%), parkinsonism (28.5%), depression (15.0%), insomnia (11.0%), nervousness or anxiety (10.3%), and akathisia (9.5%). The side effects were controlled with reduction in the dosage. TBZ is an effective and safe drug fur the treatment of a variety of hyperkinetic movement disorders, In contrast to typical neuroleptics, TBZ has not been demonstrated to cause tardive dyskinesia.